Novel cross-reactive monoclonal antibodies against ebolavirus glycoproteins show protection in a murine challenge model

Journal of Virology

Volumn 91, Issue 16, 2017, Pages

  Duehr, James ^a   Wohlbold, Teddy John ^a   Oestereich, Lisa ^b   Chromikova, Veronika ^a   Amanat, Fatima ^a   Rajendran, Madhusudan ^a   Gomez Medina, Sergio ^c   Mena, Ignacio ^a   TenOever, Benjamin R ^a   García Sastre, Adolfo ^a   Basler, Christopher F ^d   Munoz Fontela, Cesar ^b,c   Krammer, Florian ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b BERNHARD NOCHT INSTITUTE FOR TROPICAL MEDICINE   (Germany)

^c LEIBNIZ INSTITUTE FOR EXPERIMENTAL VIROLOGY   (Germany)

^d GEORGIA STATE UNIVERSITY   (United States)

Author keywords

Ebolavirus; EVD; Filovirus; Glycoprotein; MAb

Indexed keywords

CELL SURFACE PROTEIN; FC RECEPTOR; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 8H9; MONOCLONAL ANTIBODY KL 2E5; MONOCLONAL ANTIBODY KL 2H7; PLASMID DNA; PROTEIN ANTIBODY; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN; ENVELOPE GLYCOPROTEIN, EBOLA VIRUS; IMMUNOLOGIC FACTOR; VIRUS ANTIBODY; VIRUS ENVELOPE PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN BINDING; ARTICLE; CONTROLLED STUDY; CROSS REACTION; EBOLA HEMORRHAGIC FEVER; EBOLAVIRUS; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MALE; MARBURGVIRUS; MORTALITY; MOUSE; NONHUMAN; PHAGOCYTOSIS; PLASMID; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SUDAN; VACCINATION; VESICULOVIRUS; VIRUS NEUTRALIZATION; ZAIRE EBOLAVIRUS; ANIMAL; CROSS PROTECTION; DISEASE MODEL; HEMORRHAGIC FEVER, EBOLA; IMMUNOLOGY; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; CROSS PROTECTION; DISEASE MODELS, ANIMAL; EBOLAVIRUS; HEMORRHAGIC FEVER, EBOLA; IMMUNOLOGIC FACTORS; MICE; TREATMENT OUTCOME; VIRAL ENVELOPE PROTEINS;

EID: 85026319034     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00652-17     Document Type: Article

References (45)

1. Thomas A-C, Nkunzimana T, Perez Hoyos A, Kayitakire F. 2014. Impact of the West African Ebola virus disease outbreak on food security. Joint Research Centre, European Commission, Ispra, Italy. http://reliefweb. int/sites/reliefweb.int/files/resources/JRC94257_ebola_impact_on_food _security_jrc_h04_final_report.pdf.pdf
2. Evans D, Ferreira F, Panzer J. 2014. The economic impact of the 2014 Ebola epidemic: short and medium term estimates for West Africa. The World Bank Group. http://documents.worldbank.org/curated/en/524521468141287875/pdf/912190WP0see0a00070385314B00PUBLIC0. pdf
3. Pavot V. 2016. Ebola virus vaccines: where do we stand? Clin Immunol 173:44-49. https://doi.org/10.1016/j.clim.2016.10.016
4. Liu Bin W, Li ZX, Du Y, Cao GW. 2015. Ebola virus disease: from epidemiology to prophylaxis. Mil Med Res 2:7. https://doi.org/10.1186/s40779-015-0035-4
5. Gebretadik FA, Seifu MF, Gelaw BK. 2015. Review on Ebola virus disease: its outbreak and current status. Epidemiol (Sunnyvale) 5:204. https://doi. org/10.4172/2161-1165.1000204
6. Kaner J, Schaack S, Olival K, Hayman D, Paessler S, Walker D, Kuhn J, Suzuki Y, Gojobori T, Walsh P, Biek R, Real L, Vogel G, Gire S, Goba A, Andersen K, Sealfon R, Park D, Kanneh L, Jalloh S, Carroll M, Matthews D, Hiscox J, Elmore M, Pollakis G, Rambaut A, Hewson R, Simon-Loriere E, Faye O, Faye O, Koivogui L, Magassouba N, Keita S, Thiberge J-M, Lamunu M, Lutwama J, Kamugisha J, Opio A, Nambooze J, Ndayimirije N, Okware S, Borchert M, Mutyaba I, Kerkhove M, Lutwama J, Luwaga H, Bisoborwa G, Turyagaruka J, Leroy E, Kumulungui B, Pourrut X, Rouquet P, Hassanin A, Yaba P, Délicat A, Paweska J, Gonzalez J-P, Swanepoel R, Leroy E, Rouquet P, Formenty P, Souquière S, Kilbourne A, Froment J-M, Bermejo M, Raabe V, Borchert M, Rewar S, Mirdha D, Heymann D, Dowell S, Mukunu R, Ksaizek T, Khan A, Rollin P, Peters C, Bausch D, Towner J, Dowell S, Kaducu F, Lukwiya M, Sanchez A, Nichol S, Ksiazek T, Rollin P, Thorson A, Formenty P, Lofthouse C, Broutet N, Mate S, Kugelman J, Nyenswah T, Ladner J, Wiley M, Cordier-Lassalle T, Christie A, Perner A, Fowler R, Bellomo R, Roberts I, Kugelman J, Sanchez-Lockhart M, Andersen K, Gire S, Park D, Sealfon R, Lin A, Buttner S, Benjamin K, Olga D, Markus E, Tilo F, Sarah R, Jurgen E, Stephan B, Claudio R, Helmut G, Heesterbeek H, Anderson R, Andreasen V, Bansal S, Angelis D, Dye C, Eames K, Chowell G, Nishiura H, Woolhouse M, Haydon D, Antia R, Althaus C, Scarpino S, Iamarino A, Wells C, Yamin D, Ndeffo-Mbah M, Wenzel N, Fox S, Ki-moon B, Nabarro D, Baize S, Pannetier D, Oestereich L, Rieger T, Koivogui L, Magassouba N, Soropogui B, Saéz AM, Weiss S, Nowak K, Lapeyre V, Zimmermann F, Düx A, Kühl H, Takahashi S, Jessica C, Metcalf E, Ferrari M, Moss W, Truelove S, Tatem A, Grenfell B, Lessler J, Hayden E, Black B, Caluwaerts S, Achar J, Reardon S, Shultz J, Baingana F, Neria Y, Currie J, Grenfell B, Farrar J, Chang C, Ortiz K, Ansari A, Gershwin M, Chowell G, Miller M, Viboud C, Trotter C, Gay N, Edmunds WJ. 2014. Ebola virus disease in West Africa: the first 9 months of the epidemic and forward projections. N Engl J Med 371:1481-1495. https://doi.org/10.1056/NEJMoa1411100
7. Le Guenno B, Formenty P, Formentry P, Wyers M, Gounon P, Walker F, Boesch C. 1995. Isolation and partial characterisation of a new strain of Ebola virus. Lancet 345:1271-1274. https://doi.org/10.1016/S0140-6736(95)90925-7
8. Medaglini D, Harandi AM, Ottenhoff THM, Siegrist C-A, VSVEbovacConsortium. 2015 Ebola vaccine R&D: filling the knowledge gaps. Sci Transl Med 7:317ps24-317ps24. https://doi.org/10.1126/scitranslmed. aad3106
9. Schmaljohn A, Lewis GK. 2016. Cell-targeting antibodies in immunity to Ebola. Pathog Dis 74:ftw021. https://doi.org/10.1093/femspd/ftw021
10. Nissen MD. 2016. Current status of Ebolavirus vaccine development. Pathology 48:S52-S53
11. Henao-Restrepo AM, Camacho A, Longini IM, Watson CH, Edmunds WJ, Egger M, Carroll MW, Dean NE, Diatta I, Doumbia M, Draguez B, Duraffour S, Enwere G, Grais R, Gunther S, Gsell P-S, Hossmann S, Watle SV, Kondé MK, Kéïta S, Kone S, Kuisma E, Levine MM, Mandal S, Mauget T, Norheim G, Riveros X, Soumah A, Trelle S, Vicari AS, Røttingen J-A, Kieny M-P. 2017. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola ça Suffit!). Lancet 389:505-518. https://doi.org/10.1016/S0140-6736(16)32621-6
12. Qiu X, Audet J, Lv M, He S, Wong G, Wei H, Luo L, Fernando L, Kroeker A, Bovendo HF, Bello A, Li F, Ye P, Jacobs M, Ippolito G, Saphire EO, Bi S, Shen B, Gao GF, Zeitlin L, Feng J, Zhang B, Kobinger GP. 2016. Two-mAb cocktail protects macaques against the Makona variant of Ebola virus. Sci Transl Med 8:329ra33. https://doi.org/10.1126/scitranslmed.aad9875
13. Keck Z-Y, Enterlein SG, Howell KA, Vu H, Shulenin S, Warfield KL, Froude JW, Araghi N, Douglas R, Biggins J, Lear-Rooney CM, Wirchnianski AS, Lau P, Wang Y, Herbert AS, Dye JM, Glass PJ, Holtsberg FW, Foung SKH, Aman MJ. 2015. Macaque monoclonal antibodies targeting novel conserved epitopes within filovirus glycoprotein. J Virol 90:279-291. https://doi.org/10.1128/JVI.02172-15
14. Flyak AI, Shen X, Murin CD, Turner HL, David JA, Fusco ML, Lampley R, Kose N, Ilinykh PA, Kuzmina N, Branchizio A, King H, Brown L, Bryan C, Davidson E, Doranz BJ, Slaughter JC, Sapparapu G, Klages C, Ksiazek TG, Saphire EO, Ward AB, Bukreyev A, Crowe JE. 2016. Cross-reactive and potent neutralizing antibody responses in human survivors of natural ebolavirus infection. Cell 164:392-405. https://doi.org/10.1016/j.cell. 2015.12.022
15. Bornholdt ZA, Turner HL, Murin CD, Li W, Sok D, Souders CA, Piper AE, Goff A, Shamblin JD, Wollen SE, Sprague TR, Fusco ML, Pommert KBJ, Cavacini LA, Smith HL, Klempner M, Reimann KA, Krauland E, Gerngross TU, Wittrup KD, Saphire EO, Burton DR, Glass PJ, Ward AB, Walker LM. 2016 Isolation of potent neutralizing antibodies from a survivor of the 2014 Ebola virus outbreak. Science 351:1078-1083. https://doi.org/10. 1126/science.aad5788
16. Howell KA, Qiu X, Brannan JM, Bryan C, Davidson E, Holtsberg FW, Wec AZ, Shulenin S, Biggins JE, Douglas R, Enterlein SG, Turner HL, Pallesen J, Murin CD, He S, Kroeker A, Vu H, Herbert AS, Fusco ML, Nyakatura EK, Lai JR, Keck Z-Y, Foung SKH, Saphire EO, Zeitlin L, Ward AB, Chandran K, Doranz BJ, Kobinger GP, Dye JM, Aman MJ. 2016. Antibody treatment of Ebola and Sudan virus infection via a uniquely exposed epitope within the glycoprotein receptor-binding site. Cell Rep 15:1514-1526. https://doi.org/10.1016/j.celrep.2016.04.026
17. Holtsberg FW, Shulenin S, Vu H, Howell KA, Patel SJ, Gunn B, Karim M, Lai JR, Frei JC, Nyakatura EK, Zeitlin L, Douglas R, Fusco ML, Froude JW, Saphire EO, Herbert AS, Wirchnianski AS, Lear-Rooney CM, Alter G, Dye JM, Glass PJ, Warfield KL, Aman MJ. 2016. Pan-ebolavirus and panfilovirus mouse monoclonal antibodies: protection against Ebola and Sudan viruses. J Virol 90:266-278. https://doi.org/10.1128/JVI.02171-15
18. Frei JC, Nyakatura EK, Zak SE, Bakken RR, Chandran K, Dye JM, Lai JR. 2016 Bispecific antibody affords complete post-exposure protection of mice from both ebola (Zaire) and Sudan viruses. Sci Rep 6:19193. https://doi.org/10.1038/srep19193
19. Wec AZ, Nyakatura EK, Herbert AS, Howell KA, Holtsberg FW, Bakken RR, Mittler E, Christin JR, Shulenin S, Jangra RK, Bharrhan S, Kuehne AI, Bornholdt ZA, Flyak AI, Saphire EO, Crowe JE, Aman MJ, Dye JM, Lai JR, Chandran K. 2016. A "Trojan horse" bispecific-antibody strategy for broad protection against ebolaviruses. Science 354:350-354. https://doi. org/10.1126/science.aag3267
20. Holmes EC, Dudas G, Rambaut A, Andersen KG. 2016. The evolution of Ebola virus: insights from the 2013-2016 epidemic. Nature 538:193-200. https://doi.org/10.1038/nature19790
21. Moekotte AL, Huson MAM, van der Ende AJ, Agnandji ST, Huizenga E, Goorhuis A, Grobusch MP. 2016. Monoclonal antibodies for the treatment of Ebola virus disease. Expert Opin Investig Drugs 25:1325-1335. https://doi.org/10.1080/13543784.2016.1240785
22. Wei C-J, Boyington JC, McTamney PM, Kong W-P, Pearce MB, Xu L, Andersen H, Rao S, Tumpey TM, Yang Z-Y, Nabel GJ. 2010. Induction of broadly neutralizing H1N1 influenza antibodies by vaccination. Science 329:1060-1064. https://doi.org/10.1126/science.1192517
23. Leung LW, Martinez O, Reynard O, Volchkov VE, Basler CF. 2011. Ebola virus failure to stimulate plasmacytoid dendritic cell interferon responses correlates with impaired cellular entry. J Infect Dis 204: S973-S977. https://doi.org/10.1093/infdis/jir331
24. Baize S, Pannetier D, Oestereich L, Rieger T, Koivogui L, Magassouba N, Soropogui B, Sow MS, Keïta S, De Clerck H, Tiffany A, Dominguez G, Loua M, Traoré A, Kolié M, Malano ER, Heleze E, Bocquin A, Mély S, Raoul H, Caro V, Cadar D, Gabriel M, Pahlmann M, Tappe D, Schmidt-Chanasit J, Impouma B, Diallo AK, Formenty P, Van Herp M, Günther S. 2014. Emergence of Zaire Ebola virus disease in Guinea. N Engl J Med 371: 1418-1425. https://doi.org/10.1056/NEJMoa1404505
25. Furuyama W, Marzi A, Nanbo A, Haddock E, Maruyama J, Miyamoto H, Igarashi M, Yoshida R, Noyori O, Feldmann H, Takada A. 2016. Discovery of an antibody for pan-ebolavirus therapy. Sci Rep 6:20514. https://doi. org/10.1038/srep20514
26. Tran EEH, Nelson EA, Bonagiri P, Simmons JA, Shoemaker CJ, Schmaljohn CS, Kobinger GP, Zeitlin L, Subramaniam S, White JM. 2016. Mapping of Ebolavirus neutralization by monoclonal antibodies in the ZMapp Cocktail using cryo-electron tomography and studies of cellular entry. J Virol 90:7618-7627. https://doi.org/10.1128/JVI.00406-16
27. Chan KR, Ong EZ, Mok DZL, Ooi EE. 2015. Fc receptors and their influence on efficacy of therapeutic antibodies for treatment of viral diseases. Expert Rev Anti Infect Ther 13:1351-1360. https://doi.org/10. 1586/14787210.2015.1079127
28. Nimmerjahn F, Gordan S, Lux A. 2015. FcγR dependent mechanisms of cytotoxic, agonistic, and neutralizing antibody activities. Trends Immunol 36:325-336. https://doi.org/10.1016/j.it.2015.04.005
29. Ledgerwood JE, Wei C-J, Hu Z, Gordon IJ, Enama ME, Hendel CS, Mc-Tamney PM, Pearce MB, Yassine HM, Boyington JC, Bailer R, Tumpey TM, Koup RA, Mascola JR, Nabel GJ, Graham BS, VRC 306 Study Team. 2011. DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials. Lancet Infect Dis 11:916-924. https://doi. org/10.1016/S1473-3099(11)70240-7
30. Ledgerwood JE, Zephir K, Hu Z, Wei C-J, Chang L, Enama ME, Hendel CS, Sitar S, Bailer RT, Koup RA, Mascola JR, Nabel GJ, Graham BS, VRC 310 Study Team. 2013. Prime-boost interval matters: a randomized phase 1 study to identify the minimum interval necessary to observe the H5 DNA influenza vaccine priming effect. J Infect Dis 208:418-422. https://doi. org/10.1093/infdis/jit180
31. Babu TM, Levine M, Fitzgerald T, Luke C, Sangster MY, Jin H, Topham D, Katz J, Treanor J, Subbarao K. 2014. Live attenuated H7N7 influenza vaccine primes for a vigorous antibody response to inactivated H7N7 influenza vaccine. Vaccine 32:6798-6804. https://doi.org/10.1016/j. vaccine.2014.09.070
32. Halliley JL, Khurana S, Krammer F, Fitzgerald T, Coyle EM, Chung KY, Baker SF, Yang H, Martínez-Sobrido L, Treanor JJ, Subbarao K, Golding H, Topham DJ, Sangster MY. 2015. High-affinity H7 head and stalk domainspecific antibody responses to an inactivated influenza H7N7 vaccine after priming with live attenuated influenza vaccine. J Infect Dis 212: 1270-1278. https://doi.org/10.1093/infdis/jiv210
33. Krammer F, Schinko T, Palmberger D, Tauer C, Messner P, Grabherr R. 2010 Trichoplusia ni cells (High FiveTM) are highly efficient for the production of influenza A virus-like particles: a comparison of two insect cell lines as production platforms for influenza vaccines. Mol Biotechnol 45:226-234. https://doi.org/10.1007/s12033-010-9268-3
34. Wong AC, Sandesara RG, Mulherkar N, Whelan SP, Chandran K. 2010. A forward genetic strategy reveals destabilizing mutations in the Ebolavirus glycoprotein that alter its protease dependence during cell entry. J Virol 84:163-175. https://doi.org/10.1128/JVI.01832-09
35. Carette JE, Raaben M, Wong AC, Herbert AS, Obernosterer G, Mulherkar N, Kuehne AI, Kranzusch PJ, Griffin AM, Ruthel G, Dal Cin P, Dye JM, Whelan SP, Chandran K, Brummelkamp TR. 2011. Ebola virus entry requires the cholesterol transporter Niemann-Pick C1. Nature 477: 340-343. https://doi.org/10.1038/nature10348
36. Liu Q, Mena I, Ma J, Bawa B, Krammer F, Lyoo YS, Lang Y, Morozov I, Mahardika GN, Ma W, García-Sastre A, Richt JA. 2015. Newcastle disease virus-vectored H7 and H5 live vaccines protect chickens from challenge with H7N9 or H5N1 avian influenza viruses. J Virol 89:7401-7408. https://doi.org/10.1128/JVI.00031-15
37. Ayllon J, García-Sastre A, Martínez-Sobrido L. 11 October 2013. Rescue of recombinant Newcastle disease virus from cDNA. J Vis Exp. https://doi. org/10.3791/50830
38. Margine I, Palese P, Krammer F. 2013. Expression of functional recombinant hemagglutinin and neuraminidase proteins from the novel H7N9 influenza virus using the baculovirus expression system. J Vis Exp 81: e51112. https://doi.org/10.3791/51112
39. Krammer F, Margine I, Tan GS, Pica N, Krause JC, Palese P. 2012. A carboxy-terminal trimerization domain stabilizes conformational epitopes on the stalk domain of soluble recombinant hemagglutinin substrates. PLoS One 7:e43603. https://doi.org/10.1371/journal.pone. 0043603
40. Luxembourg A, Evans CF, Hannaman D. 2007. Electroporation-based DNA immunisation: translation to the clinic. Expert Opin Biol Ther 7:1647-1664. https://doi.org/10.1517/14712598.7.11.1647
41. Luxembourg A, Hannaman D, Nolan E, Ellefsen B, Nakamura G, Chau L, Tellez O, Little S, Bernard R. 2008. Potentiation of an anthrax DNA vaccine with electroporation. Vaccine 26:5216-5222. https://doi.org/10. 1016/j.vaccine.2008.03.064
42. Tan GS, Krammer F, Eggink D, Kongchanagul A, Moran TM, Palese P. 2012 A pan-H1 anti-hemagglutinin monoclonal antibody with potent broad-spectrum efficacy in vivo. J Virol 86:6179-6188. https://doi.org/10.1128/JVI.00469-12
43. Letunic I, Bork P. 2016. Interactive tree of life (iTOL) v3: an online tool for the display and annotation of phylogenetic and other trees. Nucleic Acids Res 44:W242. https://doi.org/10.1093/nar/gkw290
44. Ackerman ME, Moldt B, Wyatt RT, Dugast A-S, McAndrew E, Tsoukas S, Jost S, Berger CT, Sciaranghella G, Liu Q, Irvine DJ, Burton DR, Alter G. 2011 A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples. J Immunol Methods 366:8-19. https://doi.org/10.1016/j.jim.2010.12.016
45. Lee JE, Fusco ML, Abelson DM, Hessell AJ, Burton DR, Saphire EO. 2009. Techniques and tactics used in determining the structure of the trimeric ebolavirus glycoprotein. Acta Crystallogr D Biol Crystallogr 65: 1162-1180. https://doi.org/10.1107/S0907444909032314